Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
Vol. 41, No. 1, 2004, pp. 3-7
Bioline Code: cn04001
Full paper language: English
Document type: Research Article
Document available free of charge
Indian Journal of Cancer, Vol. 41, No. 1, 2004, pp. 3-7
© Copyright 2004 - Indian Journal Cancer.
Neoadjuvant Chemotherapy in Squamous Cell Carcinoma of the Esophagus using Low Dose Continuous Infusion 5-Fluorouracil and Cisplatin: Results of a Prospective Study|
Aroori S, Parshad R, Kapoor A, Gupta SD, Kumar A, Chattophadyay TK
BACKGROUND: Surgery is the treatment of choice for localized esophageal squamous cell carcinoma (ESCC). Despite curative surgical resection, the majority of patients develop local and systemic recurrence with poor 5-year survival. AIMS: To study the role of low dose continuous infusion (CI) 5-fluorouracil (5-FU) and
as neoadjuvant chemotherapy in ESCC. SETTINGS AND DESIGN: A non-randomized prospective study conducted over a period of two years (1996-1998) in the Department of Surgery, All India Institute of Medical Sciences, India. MATERIAL AND METHODS: Twenty-two patients with ESCC were included in the study. Chemotherapy consisted of a continuous 30-day infusion of 5-FU (350 mg/m2 /day) and cisplatin (7.5 mg/m2/day), 5 days/week for 4 weeks. All patients had surgery following chemotherapy. RESULTS: A full course of chemotherapy was completed in 18 patients (82%). Chemotherapy was not completed due to non-compliance (n=2), thrombophlebitis (n=1), and vomiting (n=1). Grade-1 haematological and hepato-toxicity was observed in four patients. Thirteen patients developed thrombophlebitis. After chemotherapy, improvement in dysphagia was observed in 13 of 22 (59%) patients. Radiological partial response was observed in 8 patients (36.4%). 19 patients underwent surgical resection (86.4%) with zero mortality. Post-operative morbidity was observed in six patients (27%). Complete and partial pathological response was observed in two (11%) and one patient (5.5%) respectively. The overall median survival was 18 months and 4-year survival was 42%. CONCLUSIONS: Low dose CI 5-FU and cisplatin is well tolerated with minimal toxicity. Histopathological response rates and survival figures are comparable with the more toxic neoadjuvant chemotherapeutic regimens.
Neoplasm, Esophageal cancer, Neoadjuvant Therapy, Fluorouracil, Cisplatin.
Alternative site location: http://www.indianjcancer.com/